or Try an Advanced Search...

    Alnylam Pharmaceuticals Stocks List

    Symbol Grade Name % Change
    RGLS F Regulus Therapeutics Inc. 0.00
    VIR D Vir Biotechnology, Inc. 3.12
    ALNY D Alnylam Pharmaceuticals, Inc. -0.80
    PRQR C ProQR Therapeutics B.V. -1.63
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Biotechnology Oligonucleotide Regulus Therapeutics Therapeutic Gene Modulation Acute Intermittent Porphyria Alpha 1 Antitrypsin Deficiency Amyloid Amyloidosis Antitrypsin Deficiency Atherosclerosis Beta Thalassemia Blastoma Carcinoma Cholesterol Clinical Development Coronavirus Cystic Fibrosis Deficiency Dimm

    Related ETFs - A few ETFs which own one or more of the above listed Alnylam Pharmaceuticals stocks.

    Symbol Grade Name Weight
    GNOM F Global X Genomics & Biotechnology ETF 5.32
    HRTS F Tema Cardiovascular and Metabolic ETF 4.95
    PBE D PowerShares Dynamic Biotech & Genome 4.78
    MNTL D Tema Neuroscience and Mental Health ETF 4.52
    MEDX F Horizon Kinetics Medical ETF 4.45
    View all Alnylam Pharmaceuticals ETFs...
    Compare ETFs
    Compare GNOM to HRTS Compare MNTL to MEDX Compare PBE to MEDX

        Alnylam Pharmaceuticals Stocks Recent News

        Date Stock Title
        Nov 18 ALNY Alnylam releases encouraging interim data on nucresiran for ATTR amyloidosis
        Nov 18 ALNY ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study
        Nov 18 ALNY Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment
        Nov 17 ALNY Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Biotechnology Oligonucleotide Regulus Therapeutics Therapeutic Gene Modulation Acute Intermittent Porphyria Alpha 1 Antitrypsin Deficiency Amyloid Amyloidosis Antitrypsin Deficiency Atherosclerosis Beta Thalassemia Blastoma Carcinoma Cholesterol Clinical Development Coronavirus Cystic Fibrosis Deficiency Dimm
        Alnylam Pharmaceuticals

        Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

        More about Alnylam Pharmaceuticals
        Browse All Tags